Company / Shareholders' Equity
Lexaria Bioscience Corp. Shareholders' Equity History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$3.0M
FY2025
5-year range
$2.5M / $13.3M
FY2021-FY2025
Trend
-62.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from $266,045 in FY2016 to $13M in FY2022.
Based on SEC 10-K filings.
$3M in FY2025 with a 10-year CAGR of +14.5%.
Remained stable around $3M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -39.1%
- 5-Year CAGR
- +4.6%
- 10-Year CAGR
- +14.5%
Key checks
Key Insights
- 5-year CAGR of +4.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 62.8% year-over-year.
- Peak shareholders' equity was recorded in FY2022.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | -62.8% |
| FY2024 | $8.0M | +164.0% |
| FY2023 | $3.0M | -77.1% |
| FY2022 | $13.3M | +434.4% |
| FY2021 | $2.5M | +4.2% |
| FY2020 | $2.4M | -13.9% |
| FY2019 | $2.8M | -7.9% |
| FY2017 | $3.0M | +1030.0% |
| FY2016 | $266.0K | -65.6% |
| FY2015 | $772.4K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026